Search
Clinician Ordering Portal
Scientific evidence
Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study
Feb 2022
Final report from a prospective study assessing the impacy of 31-GEP testing results on clinical management decisions including changes in imaging, laboratory work, and frequency of office visits. Outcomes data included.
Publication: Current Medical Research and Opinion
Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31-gene expression profile test
Oct 2021
Patient survery performed in conjunction with Melanoma Research Foundation on patient attitudes towards prognostic testing
Publication: Cancer Medicine
The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma
Sep 2021
DecisionDx-Melanoma significantly stratified patient risk for RFS, DMFS, and MSS (p < 0.001) and was a significant, independent predictor of metastatic recurrence (hazard ratio: 5.38; p = 0.014).
Publication: Future Oncology
Integrating 31-Gene expression profiling with clinicopathologic features to optimize cutaneous melanoma sentinel lymph node metastasis prediction
Sep 2021
Validation of integrated 31-GEP (i31-GEP) neural network algorithm incorporating clinicopathologic factors with the continuous 31-GEP score for personalized SLNB positivity risk assessment.
Publication: JCO Precision Oncology
Long-term outcomes in a multicenter, prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma
Apr 2021
Prospective analysis reporting long-term outcomes for patients tested with DecisionDx-Melanoma (follow-up to study first published as Hsueh, 2017).
Publication: JCO Precision Oncology
Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy
Mar 2021
GEP class was predictive of RFS and DMFS and independently predicted relapse in AJCC “low risk” (stages IA-IIA) patients.
Publication: The American Journal of Surgery
Assessment of the 31-gene expression profile test by dermatologists: a cross-sectional survey from national dermatology conferences
Mar 2021
Survey to assess the professional understanding, opinions, and clinical usage of the 31-GEP test by dermatologists.
Publication: SKIN: Journal of Cutaneous Melanoma
Risk stratification of patients with stage I cutaneous melanoma using 31-gene expression profiling
Jan 2021
Examined the prognostic value of the 31-gene expression profile (31-GEP) test for the risk of recurrence in stage I CM patients according to 31-GEP class.
Publication: Journal of Clinical and Aesthetic Dermatology
A dermatologist’s guide to implementation of gene expression profiling in the management of melanoma
Nov 2020
Expert panel of 5 leading dermatologists with 31-GEP experience convened to review literature and create a shared decision-making model/algorithm.
Publication: Journal of Clinical and Aesthetic Dermatology
Integrating the melanoma 31-gene expression profile test with surgical oncology practice within national guideline and staging recommendations
Oct 2020
Define changes in clinical management resulting from the use of the prognostic 31-gene expression profile (31-GEP) test for cutaneous melanoma in a surgical oncology practice.
Publication: Future Oncology
Integration of a 31-gene expression profile into clinical decision-making in the treatment of cutaneous melanoma
Aug 2020
Retrospective review and early experience in utilizing 31-GEP in intermediate melanomas and its effect on clinical management.
Publication: The American Surgeon
A systematic review and meta-analysis of gene expression profiling for primary cutaneous melanoma prognosis
May 2020
Systematic review of available evidence on GEP for prognosis. Included meta-analysis of 6 studies on the 31-GEP. Clinical implications show that 31-GEP can better assess prognosis leading to more appropriate patient management.
Publication: SKIN: Journal of Cutaneous Melanoma